The strong positive correlations observed between TIM3, PD-1, and PD-L1 expression in this study suggest that dual-target immunotherapy involving PD-(L)1 and TIM3 could be a valuable option for GC patients [4]. Here, HAVCR2 is linked to gastric cancer.